These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 8392903

  • 1. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
    Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco-Bianchi L.
    Cancer; 1993 Aug 01; 72(3):697-706. PubMed ID: 8392903
    [Abstract] [Full Text] [Related]

  • 2. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
    Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Wenger M, Lange W, Mertelsmann R.
    Ann Oncol; 1997 Jan 01; 8(1):49-56. PubMed ID: 9093707
    [Abstract] [Full Text] [Related]

  • 3. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T.
    J Clin Oncol; 1997 May 01; 15(5):2082-9. PubMed ID: 9164221
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD, Herndon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR.
    Am J Clin Oncol; 1997 Feb 01; 20(1):24-30. PubMed ID: 9020283
    [Abstract] [Full Text] [Related]

  • 5. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL, Palackdharry CS, Padavic K, Haas N, Kilpatrick D, Langer C, Comis R.
    J Clin Oncol; 1994 Jun 01; 12(6):1251-8. PubMed ID: 8201386
    [Abstract] [Full Text] [Related]

  • 6. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
    J Clin Oncol; 1998 Feb 01; 16(2):642-50. PubMed ID: 9469353
    [Abstract] [Full Text] [Related]

  • 7. [Dose-response effect of drugs in the chemotherapy of small-cell bronchial carcinoma].
    Kostić D, Jelić S, Radulović S.
    Srp Arh Celok Lek; 2000 Feb 01; 128(3-4):75-9. PubMed ID: 10932613
    [Abstract] [Full Text] [Related]

  • 8. Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer.
    Gridelli C, D'Aprile M, Palmeri S, Curcio C, Rossi A, Gebbia V, Veltri E, Pepe R, Pistillucci G, Bianco AR.
    Am J Clin Oncol; 1996 Dec 01; 19(6):589-91. PubMed ID: 8931678
    [Abstract] [Full Text] [Related]

  • 9. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
    Walewski J, Romejko-Jarosińska J, Zwoliński J, Falkowski S, Siedlecki P.
    Med Oncol; 1996 Dec 01; 13(4):199-205. PubMed ID: 9152970
    [Abstract] [Full Text] [Related]

  • 10. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
    Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Lange W, Mertelsmann R.
    Ann Oncol; 1999 May 01; 10(5):561-7. PubMed ID: 10416006
    [Abstract] [Full Text] [Related]

  • 11. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
    Katakami N, Takada M, Negoro S, Ota K, Fujita J, Furuse K, Ariyoshi Y, Ikegami H, Fukuoka M.
    Cancer; 1996 Jan 01; 77(1):63-70. PubMed ID: 8630941
    [Abstract] [Full Text] [Related]

  • 12. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L.
    Semin Oncol; 1995 Feb 01; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [Abstract] [Full Text] [Related]

  • 13. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov 01; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 14. Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate.
    Rosell R, Gómez-Codina J, Anton A, Sánchez JJ, Vadell C.
    Semin Oncol; 1994 Feb 01; 21(1 Suppl 1):48-53. PubMed ID: 8153657
    [No Abstract] [Full Text] [Related]

  • 15. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
    Yeung AW, Pang YK, Tsang YC, Wong SW.
    Cancer; 1994 Apr 01; 73(7):1960-70. PubMed ID: 7511042
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T.
    J Clin Oncol; 1994 Sep 01; 12(9):1833-41. PubMed ID: 7521905
    [Abstract] [Full Text] [Related]

  • 17. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Kornek G, Raderer M, Schenk T, Pidlich J, Schulz F, Globits S, Tetzner C, Scheithauer W.
    Cancer; 1995 Oct 15; 76(8):1356-62. PubMed ID: 8620409
    [Abstract] [Full Text] [Related]

  • 18. Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer.
    Havemann K, Klausmann M, Wolf M, Fischer JR, Drings P, Oster W.
    J Cancer Res Clin Oncol; 1991 Oct 15; 117 Suppl 4():S203-7. PubMed ID: 1665493
    [Abstract] [Full Text] [Related]

  • 19. Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor.
    Riccardi A, Danova M, Paccagnella A, Giordano M, Favaretto A, Panozzo M, Ghiotto C, Comis S, Fiorentino M, Chieco-Bianchi L.
    Ann Hematol; 1993 Apr 15; 66(4):185-93. PubMed ID: 8387346
    [Abstract] [Full Text] [Related]

  • 20. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR.
    J Clin Oncol; 1995 Jul 15; 13(7):1632-41. PubMed ID: 7602352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.